Skip to main content

Table 3 Secondary lung function endpoints (ITT population)

From: Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials

Endpoint

Study 207608

Study 207609

Pooled analysis

FF/UMEC/VI

N = 363

BUD/FOR+TIO

N = 365

FF/UMEC/VI

N = 366

BUD/FOR+TIO

N = 366

FF/UMEC/VI

N = 729

BUD/FOR+TIO

N = 731

0–24-h wmFEV1on Day 1,mL

n

354

355

360

356

714

711

LS mean (95% CI)

1217 (1202, 1233)

1226 (1211, 1242)

1195 (1182, 1209)

1191 (1178, 1205)

1206 (1196, 1216)

1209 (1199, 1219)

LS mean (95% CI) change from baseline

54 (39, 69)

63 (48, 78)

45 (32, 59)

41 (28, 55)

49 (39, 59)

52 (42, 62)

Treatment difference (95% CI)

−9 (−30, 13)

4 (−16, 23)

−3 (− 17, 11)

Trough FEV1on Day 2, mL

n

358

359

355

341

713

700

LS mean (95% CI)

1171 (1152,1190)

1181 (1161, 1200)

1164 (1147, 1180)

1138 (1121, 1155)

1167 (1154, 1180)

1160 (1147, 1173)

LS mean (95% CI) change from baseline

8 (−11, 27)

18 (−2, 37)

15 (−2, 32)

−10 (−28, 7)

11 (− 2, 24)

4 (−9, 17)

Treatment difference (95% CI)

− 10 (−37, 18)

26 (2, 49)

7 (− 11, 25)

Trough FEV1on Day 28, mL

n

355

353

353

354

708

707

LS mean (95% CI)

1210 (1192, 1227)

1148 (1131, 1165)

1193 (1174, 1211)

1130 (1111, 1149)

1201 (1188, 1214)

1139 (1127, 1152)

LS mean (95% CI) change from baseline

46 (29, 64)

−15 (−32, 2)

44 (25, 63)

−19 (− 37, 0)

45 (32, 58)

−16 (−29, −4)

Treatment difference (95% CI)

61 (37, 86)

63 (36, 89)

62 (44, 80)

Trough FEV1on Day 84, mL

n

344

340

346

343

690

683

LS mean (95% CI)

1203 (1185, 1221)

1145 (1127, 1164)

1173 (1153, 1193)

1119 (1099, 1139)

1188 (1174, 1201)

1132 (1118, 1146)

LS mean (95% CI) change from baseline

40 (22, 58)

−18 (−36, 1)

24 (5, 44)

−30 (−50, − 10)

32 (18, 46)

−24 (− 37, − 10)

Treatment difference (95% CI)

58 (32, 84)

54 (26, 83)

56 (37, 75)

Trough FEV1on Day 85, mL

n

341

337

343

342

684

679

LS mean (95% CI)

1189 (1169, 1208)

1151 (1131,1170)

1178 (1156, 1200)

1127 (1105, 1148)

1183 (1169, 1198)

1139 (1124, 1153)

LS mean (95% CI) change from baseline

26 (6, 45)

−12 (−32, 7)

29 (8, 51)

−22, (−44, 0)

28 (13, 42)

−17 (− 32, − 2)

Treatment difference (95% CI)

38 (10, 66)

51 (21, 82)

45 (24, 65)

  1. n number of patients with analyzable data at the current time point
  2. BUD budesonide; CI confidence interval; FEV1forced expiratory volume in 1 s; FF fluticasone furoate; FOR formoterol; ITT intent-to-treat; LS least squares; TIO tiotropium; UMEC umeclidinium; VI vilanterol; wm weighted mean